https://orcid.org/0000-0002-0640-5709
Citations (127)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Han Wang, Jun-Jie Chen, Shu-Yi Yin, Xia Sheng, Hong-Xia Wang, Wan Yee Lau, Hui Dong & Wen-Ming Cong. (2024) A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study. Journal of Hepatocellular Carcinoma 11, pages 191-206.
Read now
Read now
Vera Himmelsbach, Christine Koch, Jörg Trojan & Fabian Finkelmeier. (2024) Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?. Journal of Hepatocellular Carcinoma 11, pages 363-372.
Read now
Read now
Thi Phuong Thao Hoang, Philipp Schindler, Nikolaus Börner, Max Masthoff, Mirjam Gerwing, Philippa von Beauvais, Enrico N De Toni, Christian M Lange, Jonel Trebicka, Haluk Morgül, Max Seidensticker, Jens Ricke, Andreas Pascher, Markus Guba, Michael Ingrisch, Moritz Wildgruber & Osman Öcal. (2023) Imaging-Derived Biomarkers Integrated with Clinical and Laboratory Values Predict Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Journal of Hepatocellular Carcinoma 10, pages 2277-2289.
Read now
Read now
Ashraf Omar, Ahmed Kaseb, Tamer Elbaz, Mohamed El-Kassas, Amr El Fouly, Abdel Fatah Hanno, Ahmed El Dorry, Ahmed Hosni, Amr Helmy, Amr S Saad, Ashwaq Alolayan, Basem Elsayed Eysa, Emad Hamada, Hamdy Azim, Hany Khattab, Hesham Elghazaly, Hesham Tawfik, Hisham Ayoub, Hussein Khaled, Ibtessam Saadeldin, Imam Waked, Eman MF Barakat, Mahmoud El Meteini, Mohamed Hamed Shaaban, Mohamed EzzElarab, Mohamed Fathy, Mohamed Shaker, Mohamed Sobhi, Mohamed Kamal Shaker, Mohamed ElGharib, Mohammed Abdullah, Mohesn Mokhtar, Mostafa Elshazli, Omar Mohamed Khaleil Heikal, Osama Hetta, Reda Mahmoud ElWakil, Sameh Abdel Wahab, Samir Shehata Eid & Yousri Rostom. (2023) Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10, pages 1547-1571.
Read now
Read now
Zongyi Yin, Dongying Chen, Shuang Liang & Xiaowu Li. (2022) Neoadjuvant Therapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 9, pages 929-946.
Read now
Read now
Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Nicola Personeni & Lorenza Rimassa. (2022) Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs 31:4, pages 401-413.
Read now
Read now
Antonio D’Alessio, Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Nicola Personeni & Lorenza Rimassa. (2021) Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy 21:9, pages 927-939.
Read now
Read now
D. Brock Hewitt, Amir A. Rahnemai-Azar & Timothy M. Pawlik. (2021) Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opinion on Investigational Drugs 30:8, pages 827-835.
Read now
Read now
Josephine Tsang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Bryan Cho Wing Li, Roland Leung, Joanne Chiu, Tan to Cheung & Thomas Yau. (2021) Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology & Hepatology 15:6, pages 589-598.
Read now
Read now
Xiufeng Liu, Yi Lu & Shukui Qin. (2021) Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies. Future Oncology 17:17, pages 2243-2256.
Read now
Read now
Margherita Rimini & Andrea Casadei-Gardini. (2021) Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opinion on Investigational Drugs 30:4, pages 411-418.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy. Future Oncology 17:7, pages 755-757.
Read now
Read now
Landon L. Chan & Stephen L. Chan. (2021) Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs 26:1, pages 39-52.
Read now
Read now
Juxian Sun, Chang Liu, Dandan He, Dafeng Jiang, Shuqun Cheng & Jie Shi. A new chemotherapy strategy for advanced hepatocellular carcinoma with exrahepatic metastasis: predictors of long-term survival. Journal of Chemotherapy 0:0, pages 1-7.
Read now
Read now
Articles from other publishers (113)
Timothy E. Newhook, Susan Tsai & Funda Meric-Bernstam. (2024) Precision Oncology in Hepatopancreatobiliary Cancer Surgery. Surgical Oncology Clinics of North America 33:2, pages 343-367.
Crossref
Crossref
Prashant Bhangui. (2024) Liver transplantation and resection in patients with hepatocellular cancer and portal vein tumor thrombosis: Feasible and effective?. Hepatobiliary & Pancreatic Diseases International 23:2, pages 123-128.
Crossref
Crossref
Guosheng Yuan, Wenli Li, Mengya Zang, Rong Li, Qi Li, Xiaoyun Hu, Qi Zhang, Wei Huang, Jian Ruan, Huajin Pang & Jinzhang Chen. (2024) Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study. Discover Oncology 15:1.
Crossref
Crossref
Takahiro Osuga, Shingo Tanaka, Tomohiro Kubo, Kota Hamaguchi, Ryo Ito, Akira Sakurada, Keidai Ishikawa & Koji Miyanishi. (2024) Pulmonary Metastasectomy after Radiofrequency Ablation of Hepatocellular Carcinoma. Case Reports in Oncology, pages 407-416.
Crossref
Crossref
Parissa Tabrizian, Allen Yu, Neha Debnath, Bryan Myers & Thomas Marron. (2024) Immunotherapy and Liver Transplantation. Surgical Clinics of North America 104:1, pages 163-182.
Crossref
Crossref
Sha She, Jinzhi Shi, Jiling Zhu, Fan Yang, Jia Yu & Kai Dai. (2024) Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy. Cancer Medicine 13:4.
Crossref
Crossref
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu & Shu-Qun Cheng. (2024) Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature Medicine.
Crossref
Crossref
Xiao Xu, Ming-Da Wang, Jia-Hao Xu, Zhong-Qi Fan, Yong-Kang Diao, Zhong Chen, Hang-Dong Jia, Fu-Bao Liu, Yong-Yi Zeng, Xian-Ming Wang, Han Wu, Wei Qiu, Chao Li, Timothy M. Pawlik, Wan Yee Lau, Feng Shen, Guo-Yue Lv & Tian Yang. (2024) Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis. Frontiers in Immunology 14.
Crossref
Crossref
Adriana C. Gamboa, David A. Kooby, Shishir K. Maithel & T. Clark Gamblin. (2023) Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials. Journal of Surgical Oncology 129:1, pages 63-70.
Crossref
Crossref
Arndt Vogel, Robert C. Grant, Tim Meyer, Gonzalo Sapisochin, Grainne M. O’Kane & Anna Saborowski. (2023) Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology.
Crossref
Crossref
Wei-Qiao Zhang, Qiao Zhang, Li Tan, Zhi-Feng Guan, Feng Tian, Hong-Tao Tang, Kun He & Wei-Qiang Chen. (2023) Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients. Frontiers in Oncology 13.
Crossref
Crossref
Christina G. Dalzell, Amy C. Taylor & Sarah B. White. (2023) New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma. Cancers 15:24, pages 5749.
Crossref
Crossref
Yajuan Sun, Can Yu, Xinxin Wang, Rui Yang, ZhiPeng Ding & Yang Zhou. (2023) Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System. Journal of Gastrointestinal Surgery 27:12, pages 2787-2796.
Crossref
Crossref
Changli Liao, Guiyuan Zhang, Ruotong Huang, Linyuan Zeng, Bin Chen, Haitao Dai, Keyu Tang, Run Lin & Yonghui Huang. (2023) Inducing the Abscopal Effect in Liver Cancer Treatment: The Impact of Microwave Ablation Power Levels and PD-1 Antibody Therapy. Pharmaceuticals 16:12, pages 1672.
Crossref
Crossref
Lorenz Kocheise, Martin Schoenlein, Berit Behrends, Vincent Joerg, Christian Casar, Thorben W. Fruendt, Thomas Renné, Asmus Heumann, Jun Li, Samuel Huber, Ansgar W. Lohse, Klaus Pantel, Sabine Riethdorf, Henning Wege, Kornelius Schulze & Johann von Felden. (2023) EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma. Scientific Reports 13:1.
Crossref
Crossref
Hanyu Jiang, Chongtu Yang, Yidi Chen, Yanshu Wang, Yuanan Wu, Weixia Chen, Maxime Ronot, Victoria Chernyak, Kathryn J. Fowler, Mustafa R. Bashir & Bin Song. (2023) Development of a Model including MRI Features for Predicting Advanced-stage Recurrence of Hepatocellular Carcinoma after Liver Resection. Radiology 309:2.
Crossref
Crossref
Osman Öcal, Kerstin Schütte, Peter Malfertheiner, Thomas Berg, Christian Loewe, Heinz Josef Klümpen, Christoph Johannes Zech, Otto van Delden, Muzaffer Reha Ümütlü, Sinan Deniz, Najib Ben Khaled, Enrico Narciso De Toni, Thi Phuong Thao Hoang, Ricarda Seidensticker, Ali Aghdassi, Maciej Pech, Jens Ricke & Max Seidensticker. (2023) Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma. European Journal of Radiology 168, pages 111120.
Crossref
Crossref
Shukui Qin, Minshan Chen, Ann-Lii Cheng, Ahmed O Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C Yopp, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numata, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P Hack, Qinshu Lian, Ning Ma, Jessica H Spahn, Yulei Wang, Chun Wu, Pierce K H Chow, Alexander Thompson, Mark Danta, Pirooz Poursoltan, Andrew Kiberu, Renuka Chittajallu, Siddarth Sood, Rudolf Stauber, Matthias Pinter, Markus Peck-Radosavljevic, Jochen Decaestecker, Pieter-Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sergio De Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Faria, Cheng Tzu Yen, Leandro Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Baocai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lunxiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gaojun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Huichuan Sun, Xuetao Shi, Adrián Guzmán, Luis Corrales, Zdenek Kral, Peter Priester, Eugen Kubala, Jean Frederic Blanc, Marc Bourliere, Jean Marie Peron, Christophe Borg, Jean-Pierre Bronowicki, Nathalie Ganne, Thomas Decaens, Thomas Uguen, Alexandra Heurgue, Joerg Trojan, Maria Angeles Gonzalez-Carmona, Christoph Roderburg, Thomas Ettrich, Clemens Schotten, Arne Kandulski, Thomas Yau, Lam Chan, Mario Scartozzi, Gianluca Masi, Silvia Fanello, Pier Maria Battezzati, Francesco Leonardi, Michele Ghidini, Kazushi Numata, Manabu Morimoto, Hisashi Hidaka, Kaoru Tsuchiya, Tatsuya Yamashita, Naoya Kato, Masatoshi Kudo, Atsushi Hagihara, Hironori Koga, Tomohiro Arakawa, Ikuo Nakamura, Yusuke Kawamura, Tomokazu Kawaoka, Mitsuo Shimada, Kiyoshi Hasegawa, Hiroyuki Marusawa, Shinchiro Nakamura, Atsushi Hiraoka, Hiromitsu Hayashi, Shin Takeda, Han Chu Lee, Seung Woon Paik, Do Young Kim, Jung Il Lee, Sook-Hyang Jeong, Won Kim, Won Young Tak, Jeong Heo, Hyeyeong Kim, Hong Jae Chon, Jaeyoun Cheong, Seung Kew Yoon, Jung-Hwan Yoon, Ricardo Villalobos, Jorge Luis Martinez Rodriguez, Victor Oyervides Juarez, Carlos Alberto Hernández, Heinz-Josef Klumpen, Judith de Vos-Geelen, Edward Gane, Paola Montenegro, Cesar Torres Mattos, Ewa Janczewska, Maciej Kawecki, Ewa Nowakowska-Zajdel, Alexander Fedenko, Dmitrii Granov, Anna Alyasova, Marina Sekacheva, Evgeny Ledin, Jens Samol, Han Chong Toh, Mariona Calvo Campos, Carlos Gomez Martin, Carlos Lopez Lopez, Andres Jesus Muñoz Martin, Jose Luis Calleja Panero, Jose Luis Montero Alvarez, Maria Reig Monzón, Ignacio Delgado Mingorance, Beatriz Minguez Rosique, Ann Lii Cheng, Yi-Hsiang Huang, Shi-Ming Lin, Jee-Fu Huang, Ming-Lung Yu, Wei-Wen Su, Krittiya Korphaisarn, Kunlatida Maneenil, Chayanee Samdaengpan, Ekkapong Tharavichitkul, Mustafa Ozguroglu, Fatih Kose, Hakan Harputluoglu, Gary Buchschacher, Paul Thuluvath, Henry Xiong, Mital Patel, Philip Gold, Daneng Li, Gabriel Brooks, Ashiq Masood, Reema Patel, Ben George, Reena Salgia, Gulam Manji, Mary Crow, Ahmed Kaseb, Matthew Dugan, Kunal Kadakia, Adel Kardosh, John Gibbs, Ashesh Shah, Howard Burris III & David Hsiehchen. (2023) Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. The Lancet 402:10415, pages 1835-1847.
Crossref
Crossref
Jessica Elderkin, Najeeb Al Hallak, Asfar S. Azmi, Hussein Aoun, Jeffrey Critchfield, Miguel Tobon & Eliza W. Beal. (2023) Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management. Cancers 15:21, pages 5118.
Crossref
Crossref
Yasuyuki Tamai, Naoto Fujiwara, Takamitsu Tanaka, Shugo Mizuno & Hayato Nakagawa. (2023) Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma. Cancers 15:20, pages 5072.
Crossref
Crossref
Yutaka Endo, Muhammad Musaab Munir, Selamawit Woldesenbet, Erryk Katayama, Francesca Ratti, Hugo P Marques, François Cauchy, Vincent Lam, George A Poultsides, Minoru Kitago, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Ana Gleisner, Tom Hugh, Luca Aldrighetti, Feng Shen, Itaru Endo & Timothy M. Pawlik. (2023) Impact of Surgical Margin Width on Prognosis Following Resection of Hepatocellular Carcinoma Varies on the Basis of Preoperative Alpha-Feto Protein and Tumor Burden Score. Annals of Surgical Oncology 30:11, pages 6581-6589.
Crossref
Crossref
Jeong Il Yu, Hee Chul Park, Hyunju Shin, Hyunki Park, Sung Wook Shin, Sung Ki Cho, Dongho Hyun, Jaeseung Shin, Myung Ji Goh, Moon Seok Choi, Boram Park, Sang Min Yoon & Jinhong Jung. (2023) External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion. Radiotherapy and Oncology 187, pages 109841.
Crossref
Crossref
Christiana J. Crook & Daneng Li. (2023) Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma. Current Oncology Reports 25:10, pages 1191-1201.
Crossref
Crossref
Le Li, Pei-Sheng Wu, Xiu-Mei Liang, Kang Chen, Guan-Lan Zhang, Qi-Bin Su, Rong-Rui Huo, Rong-Wei Xie, Shan Huang, Liang Ma & Jian-Hong Zhong. (2023) Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study. Journal of Gastroenterology 58:10, pages 1043-1054.
Crossref
Crossref
Jae Hyun Yoon & Sung Kyu Choi. (2023) Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. Journal of Liver Cancer 23:2, pages 300-315.
Crossref
Crossref
Charles-Henri Wassmer, Sofia El Hajji, Xenofon Papazarkadas, Philippe Compagnon, Parissa Tabrizian, Stéphanie Lacotte & Christian Toso. (2023) Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers 15:18, pages 4574.
Crossref
Crossref
Yujie Huang, Yu Zhang, Mingyu Zhang, Kai Zhao, Lina Feng, Jialun Guan, Ruonan Dong, Jingmei Liu, Dean Tian, Mei Liu, Suhong Xia & Jiazhi Liao. (2023) Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect. Critical Reviews in Oncology/Hematology 189, pages 104070.
Crossref
Crossref
Zhi-Xi Li, Qi-Fan Zhang, Jia-Ming Huang, Shao-Jian Huang, Han-Biao Liang, Hao Chen, Zhan-Hong Lai, Qing-Yan Li, Jian-Ping Qian, Kai Wang & Jie Zhou. (2023) Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 47:7, pages 102165.
Crossref
Crossref
Carlo Saitta & Giuseppe Cabibbo. (2023) Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of “drug class change”. Digestive and Liver Disease 55:7, pages 831-832.
Crossref
Crossref
Justin H. Lo, Rajiv Agarwal, Laura W. Goff & Thatcher R. Heumann. (2023) Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies. Cancers 15:13, pages 3312.
Crossref
Crossref
Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang & Zhi-yong Huang. (2023) Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Frontiers in Immunology 14.
Crossref
Crossref
Shuanggang Chen, Binyan Shen, Ying Wu, Lujun Shen, Han Qi, Fei Cao, Tao Huang, Hongtong Tan, Chunyong Wen & Weijun Fan. (2023) The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. International Immunopharmacology 119, pages 110228.
Crossref
Crossref
Satoshi Takakusagi, Hinako Tanaka, Atsushi Naganuma, Satoru Kakizaki, Kei Shibuya, Tatsuya Ohno, Hitoshi Takagi & Toshio Uraoka. (2023) Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Clinical Journal of Gastroenterology 16:3, pages 407-415.
Crossref
Crossref
Majd B Aboona, Wendi Zhou & Karn Wijarnpreecha. (2023) A Rare Type of Hepatocellular Carcinoma Presenting With Cardiac Thrombus. Cureus.
Crossref
Crossref
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis & Ernesto Claar. (2023) Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?. Cancers 15:11, pages 2950.
Crossref
Crossref
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong & Dan Yi. (2023) Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma. Frontiers in Oncology 13.
Crossref
Crossref
Er-lei Zhang. (2023) Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Bin Li, Juan Jin, Duancheng Guo, Zhonghua Tao & Xichun Hu. (2023) Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers 15:10, pages 2858.
Crossref
Crossref
Pantzios Spyridon, Syriha Antonia, Mandilara Dionysia, Stathopoulou Ioanna, Barla Georgia, Ptohis Nikolaos, Galanis Petros & Elefsiniotis Ioannis. (2023) Efficacy of Αtezolizumab–Βevacizumab in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression, the type of BCLC-C and liver disease severity. Journal of Cancer Research and Clinical Oncology.
Crossref
Crossref
James Moroney, Juan Trivella, Ben George & Sarah B. White. (2023) A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence. Cancers 15:10, pages 2791.
Crossref
Crossref
Shihai Liu. 2023. Liver Cancer - Genesis, Progression and Metastasis. Liver Cancer - Genesis, Progression and Metastasis.
Max Seidensticker, Osman Öcal, Kerstin Schütte, Peter Malfertheiner, Thomas Berg, Christian Loewe, Heinz Josef Klümpen, Otto van Delden, Muzaffer Reha Ümütlü, Najib Ben Khaled, Enrico Narciso de Toni, Ricarda Seidensticker, Ali Aghdassi, Albert Tran, Jean-Pierre Bronowicki, Bora Peynircioglu, Bruno Sangro, Maciej Pech & Jens Ricke. (2023) Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. JHEP Reports 5:5, pages 100699.
Crossref
Crossref
Daniel Hoffman, Amy Shui, Ryan Gill, Shareef Syed & Neil Mehta. (2023) Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection. Cancers 15:9, pages 2433.
Crossref
Crossref
Takuya Minagawa, Osamu Itano, Minoru Kitago, Yuta Abe, Hiroshi Yagi, Taizo Hibi, Masahiro Shinoda, Hidenori Ojima, Michiie Sakamoto & Yuko Kitagawa. (2023) Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience. Cancers 15:8, pages 2320.
Crossref
Crossref
Lixing Liu, Hao Li, Peijin Li, Rui Zhou, Qinglin Zhang, Tingting Liu & Li Feng. (2023) Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice. Iranian Journal of Pharmaceutical Research 22:1.
Crossref
Crossref
Zeta Chow, Evans Amoah, Zhonglin Hao & Mahesh Kudrimoti. (2023) Radiotherapy in Managing Metastatic Hepatocellular Carcinoma With Cardiac Involvement and Pulmonary Tumor Thromboemboli: A Case Report. Cureus.
Crossref
Crossref
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa & Takashi Kumada. (2022) Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study. Cancer Medicine 12:5, pages 5293-5303.
Crossref
Crossref
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Humaid O. Al-Shamsi, Milind Javle, Ashish Saharia, Ashton A. Connor, Sudha Kodali, Rafik M. Ghobrial & Maen Abdelrahim. (2023) Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers 15:5, pages 1433.
Crossref
Crossref
Gabriela Azevedo Solino, Raphael Paiva Cock Paiva Cock Ferreira, Luiz Augusto Carneiro D’Albuquerque, Alberto Queiroz Farias, Lívia Zardo Trindade, Vitor Fiorin de Vasconcelos & Mariana Poltronieri Pacheco. (2023) Atezolizumabe mais Bevacizumabe como Ponte para Transplante Hepático no Carcinoma Hepatocelular. Brazilian Journal of Transplantation 26:1.
Crossref
Crossref
Gabriela Azevedo Solino, Raphael Paiva Cock Paiva Cock Ferreira, Luiz Augusto Carneiro D’Albuquerque, Alberto Queiroz Farias, Lívia Zardo Trindade, Vitor Fiorin de Vasconcelos & Mariana Poltronieri Pacheco. (2023) Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma. Brazilian Journal of Transplantation 26:1.
Crossref
Crossref
Lei Jiang, Luan Li, Yongzhuang Liu, Meixiao Zhan, Ligong Lu, Shengtao Yuan & Yanyan Liu. (2023) Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Frontiers in Pharmacology 14.
Crossref
Crossref
Daniel W. Nelson & Jean-Nicolas Vauthey. (2022) Optimizing Treatment Strategies with Preoperative Assessment for Microvascular Invasion in Hepatocellular Carcinoma. Annals of Surgical Oncology 30:2, pages 660-662.
Crossref
Crossref
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa & Takashi Kumada. (2022) Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab. Hepatology International 17:1, pages 86-96.
Crossref
Crossref
Weijie Ma, Ruobing Xue, Zheng Zhu, Hizra Farrukh, Wenru Song, Tianhong Li, Lei Zheng & Chong-xian Pan. (2023) Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng & Ying-Tang Gao. (2023) Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 15:1, pages 1-18.
Crossref
Crossref
Miao-Fen Chen, Ping-Tsung Chen, Ching-Chuan Hsieh & Chih-Chi Wang. (2023) Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma. Cells 12:2, pages 332.
Crossref
Crossref
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova & Ju Dong Yang. (2023) Recent advances in the management of hepatocellular carcinoma. Clinical and Molecular Hepatology 30:1, pages 1-15.
Crossref
Crossref
Jeremy D Kratz & Nataliya V Uboha. (2023) Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers. Oncology & Haematology 19:2, pages 1.
Crossref
Crossref
Masatoshi Kudo. (2023) Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma. Liver Cancer 12:3, pages 189-197.
Crossref
Crossref
Nicole M. Nevarez, Gloria Y. Chang & Adam C. Yopp. (2023) An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 32:1, pages 101-117.
Crossref
Crossref
Cyprien Toubert, Boris Guiu, Bader Al Taweel, Eric Assenat, Fabrizio Panaro, François-Regis Souche, Jose Ursic-Bedoya, Francis Navarro & Astrid Herrero. (2022) Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!. Cancers 15:1, pages 232.
Crossref
Crossref
Zhao-Shan Niu, Wen-Hong Wang & Xiao-Jun Niu. (2022) Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. World Journal of Gastroenterology 28:46, pages 6433-6477.
Crossref
Crossref
Margot T.M. Reinders, Karel J. van Erpecum, Maarten L.J. Smits, Arthur J.A.T. Braat, Joep de Bruijne, Rutger Bruijnen, Dave Sprengers, Robert A. de Man, Erik Vegt, Jan N.M. IJzermans, Adriaan Moelker & Marnix G.E.H. Lam. (2022)
Safety and Efficacy of
166
Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study
. Journal of Nuclear Medicine 63:12, pages 1891-1898.
Crossref
Crossref
Meng Yuan, Li Liu, Chenlin Wang, Yan Zhang & Jiandong Zhang. (2022) The Complement System: A Potential Therapeutic Target in Liver Cancer. Life 12:10, pages 1532.
Crossref
Crossref
Angelica Singh, Sofia Zahid, Ilya Noginskiy, Timothy Pak, Soeb Usta, Marina Barsoum & Uqba Khan. (2022) A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology 29:9, pages 6445-6462.
Crossref
Crossref
Li Yin, Xing-yu Li, Lin-lin Zhu, Gui-lai Chen, Zhuo Xiang, Qing-qing Wang, Jing-wang Bi & Qiang Wang. (2022) Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Franziska Füchsl & Angela M. Krackhardt. (2022) Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers 14:17, pages 4192.
Crossref
Crossref
Zhiwei Wang, Mingxing Li, Yuanfeng Liu, Zhentao Qiao, Ling Yang, Bo Liu & Tao Bai. (2022) CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex. Cancer Gene Therapy 29:8-9, pages 1217-1227.
Crossref
Crossref
Santhasiri Orrapin, Sasimol Udomruk, Worakitti Lapisatepun, Sutpirat Moonmuang, Areerak Phanphaisarn, Phichayut Phinyo, Dumnoensun Pruksakorn & Parunya Chaiyawat. (2022) Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers 14:14, pages 3373.
Crossref
Crossref
Joseph W. Franses & Andrew X. Zhu. (2022) Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present. Clinical Cancer Research 28:13, pages 2738-2743.
Crossref
Crossref
Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Narmin Ghaffari Laleh, Daniele Sommacale, Alexis Laurent, Giuliana Amaddeo, David Gentien, Audrey Rapinat, Hélène Regnault, Cécile Charpy, Cong Trung Nguyen, Christophe Tournigand, Raffaele Brustia, Jean Michel Pawlotsky, Jakob Nikolas Kather, Maria Chiara Maiuri, Nicolas Loménie & Julien Calderaro. (2022) Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. Journal of Hepatology 77:1, pages 116-127.
Crossref
Crossref
Naoto Saito, Takeshi Hatanaka, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga, Kenji Kashiwabara, Norio Kubo, Yasuo Hosouchi, Hiroki Tojima, Satoru Kakizaki & Toshio Uraoka. (2022) A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clinical Case Reports 10:7.
Crossref
Crossref
Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas & Peter Robert Galle. (2022) Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 75:6, pages 1604-1626.
Crossref
Crossref
Jeong Il Yu, Wonseok Kang, Gyu Sang Yoo, Myung Ji Goh, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Jung Yong Hong, Ho Yeong Lim, Boram Park & Hee Chul Park. (2022) Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. Frontiers in Oncology 12.
Crossref
Crossref
Natasha Chandok, Sanjeev Sirpal & Eric M Yoshida. (2022)
Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the
Squid Game
. Canadian Liver Journal 5:2, pages 165-168.
Crossref
Crossref
Xing He, Yaorong Peng, Zhenyu Zhou & Wenbin Li. (2022) Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review. Frontiers in Oncology 12.
Crossref
Crossref
Ziqi HouJie LiuZhaoxing JinGuoteng QiuQingyun XieShizheng MiJiwei Huang. (2022) Use of chemotherapy to treat hepatocellular carcinoma. BioScience Trends 16:1, pages 31-45.
Crossref
Crossref
Zhu-Jian Deng, Le Li, Yu-Xian Teng, Yu-Qi Zhang, Yu-Xin Zhang, Hao-Tian Liu, Jian-Li Huang, Zhen-Xiu Liu, Liang Ma & Jian-Hong Zhong. (2021) Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology 10:1, pages 147-158.
Crossref
Crossref
Carolin Ploeger, Johannes Schreck, Thorben Huth, Angelika Fraas, Thomas Albrecht, Alphonse Charbel, Junfang Ji, Stephan Singer, Kai Breuhahn, Stefan Pusch, Bruno Christian Köhler, Christoph Springfeld, Peter Schirmacher, Arianeb Mehrabi, Benjamin Goeppert & Stephanie Roessler. (2022) STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers 14:5, pages 1154.
Crossref
Crossref
Osman Öcal, Daniel Rössler, Jens Ricke & Max Seidensticker. (2022) Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. Digestive Diseases 40:4, pages 458-467.
Crossref
Crossref
Ling Li & Florin M. Selaru. 2022. Hepatobiliary Cancers: Translational Advances and Molecular Medicine. Hepatobiliary Cancers: Translational Advances and Molecular Medicine
319
341
.
Lucia Morbidelli. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
241
260
.
Friedrich Foerster & Peter Robert Galle. 2023. Immune Strategies for Gastrointestinal Cancer. Immune Strategies for Gastrointestinal Cancer
177
183
.
Fei Cao, Yi Yang, Tongguo Si, Jun Luo, Hui Zeng, Zhewei Zhang, Duiping Feng, Yi Chen & Jiaping Zheng. (2021) The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Frontiers in Oncology 11.
Crossref
Crossref
Rafael S. Rios, Kenneth I. Zheng & Ming-Hua Zheng. (2021) Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chinese Medical Journal 134:24, pages 2911-2921.
Crossref
Crossref
Faiza Ahmed, Jennifer Onwumeh-Okwundu, Zeynep Yukselen, Maria-Kassandra Endaya Coronel, Madiha Zaidi, Prathima Guntipalli, Vamsi Garimella, Sravya Gudapati, Marc Darlene Mezidor, Kim Andrews, Mohamad Mouchli & Endrit Shahini. (2021) Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World Journal of Gastrointestinal Oncology 13:11, pages 1813-1832.
Crossref
Crossref
Binfeng Wang, Miaomiao Ma, Xiaojun Guo, Yan Yan & Lang Li. (2021) Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk. Medicine 100:41, pages e27527.
Crossref
Crossref
Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi & Seung Kew Yoon. (2021) Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. International Journal of Molecular Sciences 22:19, pages 10271.
Crossref
Crossref
Yung-Yeh Su, Chia-Chen Li, Yih-Jyh Lin & Chiun Hsu. (2021) Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease 41:03, pages 263-276.
Crossref
Crossref
Jingye Li, Jinrong Xu & Zhibing Li. (2021) Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Translational Oncology 14:8, pages 101116.
Crossref
Crossref
Jamal Majidpoor & Keywan Mortezaee. (2021) Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology 44:4, pages 715-737.
Crossref
Crossref
Tsung‐Che Wu, Ying‐Chun Shen & Ann‐Lii Cheng. (2021) Evolution of systemic treatment for advanced hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences 37:8, pages 643-653.
Crossref
Crossref
Chunye Zhang & Ming Yang. (2021) The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers 13:15, pages 3740.
Crossref
Crossref
Shao-Li Huang, Yu-Ming Wang, Quan-Yue Wang, Guang-Gui Feng, Fu-Qing Wu, Liu-Ming Yang, Xi-He Zhang & Hong-Wu Xin. (2021) Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Frontiers in Genetics 12.
Crossref
Crossref
Yuichi Honma, Michihiko Shibata, Tomonori Gohda, Hiroki Matsumiya, Keiichiro Kumamoto, Aya Miyama, Kahori Morino, Yudai Koya, Akihiro Taira, Shinji Shinohara, Tsuguru Hayashi, Masashi Kusanaga, Shinji Oe, Koichiro Miyagawa, Shintaro Abe, Fumihiro Tanaka & Masaru Harada. (2021) Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab. Internal Medicine 60:12, pages 1847-1853.
Crossref
Crossref
Maria Tampaki, George Vasileios Papatheodoridis & Evangelos Cholongitas. (2021) Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clinical Journal of Gastroenterology 14:3, pages 699-713.
Crossref
Crossref
Jintu Chen, Canwei Chen, Yongfa Lin, Yongfa Su, Xueping Yu, Yancheng Jiang, Zixuan Chen, ShaoYing Ke, ShaoZe Lin, LiangJuan Chen, Zhishan Zhang & Tao Zhang. (2021)
Downregulation of
SUMO2
inhibits hepatocellular carcinoma cell proliferation, migration and invasion
. FEBS Open Bio 11:6, pages 1771-1784.
Crossref
Crossref
Konstantinos Damiris, Hamza Abbad & Nikolaos Pyrsopoulos. (2021) Cellular based treatment modalities for unresectable hepatocellular carcinoma. World Journal of Clinical Oncology 12:5, pages 290-308.
Crossref
Crossref
Fabiola Milosa, Rosina Maria Critelli, Simone Lasagni, Alessandra Pivetti, Lorenza Di Marco, Dante Romagnoli, Lucia Carulli, Francesco Dituri, Serena Mancarella, Gianluigi Giannelli, Maria‐Luz Martinez‐Chantar, Luca Fabris & Erica Villa. (2021) Prognostic significance of hypoxic and metabolic gene profiling in hepatocellular carcinoma. Liver Cancer International 2:1, pages 15-26.
Crossref
Crossref
Amisha Singh, Ryan J. Beechinor, Jasmine C. Huynh, Daneng Li, Farshid Dayyani, Jennifer B. Valerin, Andrew Hendifar, Jun Gong & May Cho. (2021) Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers 13:9, pages 2164.
Crossref
Crossref
Friedrich Foerster & Peter Robert Galle. (2021) The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers 13:8, pages 1962.
Crossref
Crossref
Xin Li, Yaxi Wang, Xin Ye & Ping Liang. (2021) Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Zhu Zeng, Biao Yang & Zhengyin Liao. (2021) Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Frontiers in Oncology 11.
Crossref
Crossref
Robyn Laube, Abdul‐Hamid Sabih, Simone I Strasser, Lynn Lim, Maria Cigolini & Ken Liu. (2020) Palliative care in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 36:3, pages 618-628.
Crossref
Crossref
Chihiro ITO, Katsunori SAKAMOTO, Miku IWATA, Kei TAMURA, Akihiro TAKAI, Riko KITAZAWA & Yasutsugu TAKADA. (2021) Case of Recurrent Hepatocellular Carcinoma with Tumor Thrombi Formation in the Omental Vein大網静脈に腫瘍栓を形成した再発肝細胞癌の1例. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 82:12, pages 2270-2274.
Crossref
Crossref
Masatoshi Kudo. (2021) Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma. Liver Cancer 10:5, pages 399-403.
Crossref
Crossref
Ayano Kabashima, Shu Shimada, Masahiro Shimokawa, Yoshimitsu Akiyama, Minoru Tanabe & Shinji Tanaka. (2021) Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of Hepato-Biliary-Pancreatic Sciences 28:1, pages 62-75.
Crossref
Crossref
Soumya Jogi, Radha Varanai, Sravani S. Bantu & Ashish Manne. (2020) Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncology Reviews 14:2.
Crossref
Crossref
Jiao Feng, Jingjing Li, Liwei Wu, Qiang Yu, Jie Ji, Jianye Wu, Weiqi Dai & Chuanyong Guo. (2020) Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Hanna Javan, Farshid Dayyani & Nadine Abi-Jaoudeh. (2020) Therapy in Advanced Hepatocellular Carcinoma. Seminars in Interventional Radiology 37:05, pages 466-474.
Crossref
Crossref
Stephen P. Hack, Andrew X. Zhu & Yulei Wang. (2020) Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology 11.
Crossref
Crossref
Takashi KokudoNorihiro Kokudo. (2020) What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?. Global Health & Medicine 2:5, pages 265-268.
Crossref
Crossref
Lei Wu, Wen Quan, Qiong Luo, Ying Pan, Dongxu Peng & Guihai Zhang. (2020) Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences 7.
Crossref
Crossref